← All Articles
Metabolic
Understanding GLP-1 Receptor Agonists
Irvine Health Editorial
2025-11-08
9 min read
Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally produced in the L-cells of the small intestine and colon in response to food intake. GLP-1 receptor agonists (GLP-1 RAs) are a class of peptide therapies that mimic this hormone's actions at its receptor, producing effects that include enhanced insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite. The class now includes multiple approved agents — liraglutide, semaglutide, dulaglutide, and tirzepatide (as a dual agonist) — and has transformed the clinical landscape of metabolic medicine over the past decade.
The Science Behind GLP-1
Native GLP-1 has a circulating half-life of only 1–2 minutes, rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonist peptides are engineered to resist DPP-4 degradation, extending activity to hours or days. Importantly, GLP-1 receptors are expressed not only in the pancreas but in the cardiovascular system, kidneys, liver, lungs, and brain — which explains the broad systemic effects observed in clinical trials beyond blood sugar alone.
Central Appetite Regulation — Kanoski et al., Neuropharmacology (2016 Review)
Research has identified GLP-1 receptor expression in key hypothalamic nuclei and brainstem regions involved in energy homeostasis and reward processing. GLP-1 receptor agonism in the central nervous system reduces hedonic eating behavior and modulates dopamine signaling — providing a mechanistic basis for reduced food cravings observed clinically.
Cardiorenal Protection — Mann et al. / Marso et al., NEJM (2016–2017)
The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) demonstrated statistically significant reductions in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, establishing GLP-1 RAs as a class with pleiotropic cardiovascular benefits beyond glycemic control.
Different Agents, Different Profiles
- Liraglutide (Victoza/Saxenda): Daily injection; first GLP-1 RA approved for weight management.
- Semaglutide (Ozempic/Wegovy): Weekly injection; substantially greater weight reduction than liraglutide in head-to-head data.
- Dulaglutide (Trulicity): Weekly injection; strong cardiovascular outcomes data (REWIND trial).
- Tirzepatide (Mounjaro/Zepbound): Weekly injection; dual GIP/GLP-1 agonist with superior weight-loss outcomes to single GLP-1 agents in trials.
Who May Be Evaluated for GLP-1 Therapy
Clinical guidelines from organizations including the American Diabetes Association (ADA) and the Obesity Society suggest considering GLP-1 RAs in adults with type 2 diabetes requiring glycemic management, and in adults with obesity or overweight with at least one weight-related comorbidity. A prescribing physician evaluates each patient's complete medical history, current medications, contraindications, and goals before determining appropriateness.
References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
- Kanoski SE, et al. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885-895.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
Explore More Articles
Browse our full library of evidence-based peptide research.
View All Posts
*The assessment made available on the Irvine Health website does not create a doctor-patient relationship between the individual completing the assessment and Irvine Health. Irvine Health partners with a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety. The answers an individual provides to the Irvine Health assessment consequently determine if the individual is screened out of eligibility for medication, and an Irvine Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. Irvine Health clinicians retain the decision to prescribe compounded medications to patients.
All claims and benefits on this website refer to self-reported data from customers on a treatment plan that includes compounded medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3–4 weeks thereafter. Results from compounded medications found on the Irvine Health platform may vary and be affected by an individual’s adherence to the program and their clinician’s recommendations. Compounded peptides and GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider’s medical judgment, which is informed by a telehealth consultation and medical history.
We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Irvine Health does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.
Pharmacy Providers
We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.
*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs, and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.
Medication is included in the cost of the Irvine Health Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by Irvine Health affiliated physicians and licensed professional corporations. No data, photos, claims, or any other information is associated with results derived from clinical trials, studies, or public information and is always representative of Irvine Health patient experience.
Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content.
© 2026 Irvine Health LLC. All rights reserved. 19200 Von Karman Avenue, 4th, 5th, and 6th Floors, Irvine, CA 92612.